Abstract Details

Title The Effect of High Dose Orally Disintegrated Tablet Selegiline (ODT-S: Zelapar[reg]), a Selective Monoamine Oxidase B Inhibitor (MAO-B), on Monoamine Oxidase A (MAO-A), and Compared to EMSAM[reg] (Transdermal Formulation of Selegiline)

Topic Movement Disorders

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Stanley Fahn, MD, FAAN	Dr. Fahn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Stoparkinson Healthcare Systems, LLC; . Dr. Fahn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin Inc . Dr. Fahn has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Publishers . Dr. Fahn has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Kirkland & Ellis. Dr. Fahn has received publishing royalties from a publication relating to health care.
Fred C. McCall, PhD (Valeant Pharmacetuticals)	No disclosure on file
Janet M. Hammond, MD, PhD (Valeant Pharmaceuticals)	No disclosure on file
Frank W. Telang, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Frederick W. Foley, PhD (Yeshiva University)	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��